Nathan Karin is a leading scientist in molecular and cellular immunology. His major discovery (Nature, 1992) led to the development of the first FDA approved biological drug for Multiple Sclerosis. After graduating the Hebrew University Nathan joined the Weizmann Inst. for a Ph.D. thesis followed by a postdoctoral fellowship at Stanford University School of Medicine, both in world leading laboratories in immunology and Neuroimmunology focusing on exploring the molecular basis of self- non-self recognition in autoimmune disease, with a particular interest in Multiple Sclerosis. Nathan Karin published more then 70 manuscripts, most in leading and very leading journals (Nature, Science, Immunity, JCI, JEM, PNAS, Cell Reports and others). In many of them his students have been assigned as senior authors. Among the students that have graduated the lab are leading scientists in the academics/hospitals and industry in Israel and Aboard. Among them: Dr. Yaniv Zohar (Physician & Principle Investigator RAMBAM hospital and Rapaport Faculty of Medicine), Dr. Uri Weinberg (Physician and CEO, Industry, Israel), Dr. Tal Gazit, (Physician & Assistant Professor Washington University, USA), Dr Nir Grabia, (Senior Scientist and lab manager Harvard University), Dr. Moran Meiron, (CEO, Industry, Israel), Dr. Yair Sapir (CEO, Industry, Israel), Dr. Rachel Anunu (Senior Scientist and lab manger Haifa University), Dr. Yiftah Barsheshet (Senior Scientist and lab manger Bar Ilan University), Dr Sawsan Youssef (CEO, Industry USA), Dr Liat Izhak (senior scientists at a very leading company, USA) and others.